Analyst Price Target is $9.20
▲ +938.02% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Gossamer Bio in the last 3 months. The average price target is $9.20, with a high forecast of $15.00 and a low forecast of $4.00. The average price target represents a 938.02% upside from the last price of $0.89.
Current Consensus is
Buy
The current consensus among 5 investment analysts is to buy stock in Gossamer Bio. This Buy consensus rating has held steady for over two years.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Read More